NCT06895369View on ClinicalTrials.gov

The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2033

Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
DRUG

Pucotenlimab

patients will receive 3 cycles of pucotenlimab combined with TP (cisplatin + docetaxel) as neoadjuvant therapy, followed by standard surgical treatment

Trial Locations (1)

310016

Sir Run Run Shaw Hospital, Hanzhou

All Listed Sponsors
lead

Sir Run Run Shaw Hospital

OTHER